Aclarion, Inc.

Listed Company

ACONWCIK 0001635077NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$75.7K

Net Income

$-7.23M

Total Assets

$13.67M

Equity

$12.84M

Shares Out

2.28M

Op. Cash Flow

$-7.16M

Business

Aclarion, Inc. is a healthcare technology company that leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatment decisions for discogenic low back and neck pain. Its primary offerings include the NOCISCAN product suite—NOCICALC spectral processing and NOCIGRAM reporting—that post-process MRS data into biomarkers and NOCISCOREs to identify painful versus non-painful discs. The company operates as a single operating and reporting segment focused on diagnostic post-processing software, AI research, and clinical registries. Aclarion distributes via compatible MRI sites, imaging centers, hospitals, strategic partners, direct patient pay and payer reimbursement channels in the United States and internationally.

Summary from filing dated 2025-04-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	75,730	45,724	75,404	60,444	60,292
Cost of revenue	68,902	84,658	75,728	65,298	69,175
Gross profit (loss)	6,828	−38,934	−324	−4,854	−8,883
Sales and marketing	2	976,554	757,004	498,003	330,814
Research and development	1	888,766	873,336	1	787,850
General and administrative	4	4	3	4	2
Total operating expenses	7	5	5	6	3
Loss from operations	−7	−6	−5	−6	−3
Interest expense	0	−535,470	−608,288	—	—
Loss on exchange of debt	0	−1	0	—	—
Gain on extinguishment of debt	73,272	6,058	—	—	—
Changes in fair value of warrant and derivative liabilities	11,806	335,033	646,319	0	—
Penalties and settlements	−672,625	−212,453	0	—	—
Interest income	411,061	318	—	—	—
Other, net	−4,752	−49	−562	521	4,458
Total other expense	−181,238	−1	−35,393	−2	−2
Loss before income taxes	−7	−7	−5	−7	—
Income tax provision	0	0	0	0	0
Net loss	−7	−7	−5	−7	−5
Dividends on preferred stock	−6,683	−59,675	0	−415,523	−1
Net loss allocable to common stockholders	−7	−7	−5	−7	−6
Net loss per share allocable to common stockholders, basic	−13.61	−7,479	−79,782	−19.61	−6.58
Net loss per share allocable to common stockholders, diluted	−13.61	−7,479	−79,782	−19.61	−6.58
Weighted average shares of common stock outstanding, basic	532,036	943	62	381,598	905,685
Weighted average shares of common stock outstanding, diluted	532,036	943	62	381,598	905,685

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	12	453,661	1	1	432,530
Restricted cash	25,000	10,000	10,000	10,000	20,000
Accounts receivable, net	29,680	18,326	13,270	18,569	6,280
Prepaid expense	316,235	0	245,030	199,701	273,394
Other current assets	10,000	39,002	—	—	—
Total current assets	12	824,279	1	2	732,204
Property and equipment, net	24,169	5,499	1,782	3,346	12,636
Intangible assets, net	1	1	1	1	1
Total non-current assets	1	1	1	1	1
Total assets	14	2	2	3	2
Accounts payable	324,470	531,603	760,535	462,202	1
Accrued and other liabilities	504,262	404,228	857,722	226,469	696,582
Warrant liability	63	11,869	121,326	0	—
Liability to issue equity	0	80,772	33,297	0	0
Total current liabilities	837,287	1	3	688,671	8
Total liabilities	837,287	1	—	—	—
Commitments and contingencies (see Note 11)	—	—	—	—	—
Additional paid-in capital	71	52	44	42	19
Accumulated deficit	−58	−51	−44	−39	−32
Total stockholders equity	13	970,057	−727,995	2	−13
Total liabilities and stockholders equity	14	2	2	3	2

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	227,406	193,139	162,670	—	—
Share-based compensation	105,368	287,455	456,001	1	177,489
Amendment of warrants	48,087	0	—	—	—
Non-cash settlements	58,272	0	—	—	—
Loss on extinguishment of debt	0	111,928	0	—	—
Amortization of deferred issuance costs	0	471,387	497,656	0	—
Change in fair value related to warrants and derivative	−11,806	−335,033	−646,319	0	—
Non-cash interest related to bridge funding	0	58,002	98,685	0	—
Non-cash expenses related to equity line agreement	0	425,367	0	—	—
Accounts receivable	−11,354	7,271	−1,491	−12,290	16,222
Prepaids and other current assets	16,057	−287,663	−38,539	−87,522	−210,765
Accounts payable	−198,641	−156,403	220,633	−603,102	199,604
Accrued and other liabilities	−163,964	−127,449	448,459	−113,893	509,806
Net cash used in operating activities	−7	−5	−4	−5	−2
Intangible assets Patents	−182,374	−316,822	−119,522	−208,870	−102,005
Fixed assets	−21,528	−5,115	0	—	—
Net cash used in investing activities	−203,902	−321,937	−119,522	−207,870	−102,005
Public offering of common stock and warrants	15	3	—	—	—
Registered direct offerings of common stock	6	0	0	9	—
Proceeds from direct offering of prefunded warrants	2	0	—	—	—
Proceeds from sale of preferred stock	0	1	1,000	0	—
Proceeds from sale of common stock and warrants, ATM	0	288,294	—	—	—
Common stock cash issuance costs	−2	−788,099	0	−365,060	—
Exercise of Series C warrants	336,441	0	—	—	—
Redemption of Series B Preferred stock	−1	0	—	—	—
Proceeds from common stock and warrant RegA+ offering	0	529,254	—	—	—
Proceeds from equity line	0	2	1	0	—
Repayment of promissory notes	0	−300,973	0	−2	0
Equity line cash issuance costs	0	−367,865	−74,916	—	—
Preferred stock cash issuance costs	0	−90,000	0	—	—
Net cash provided by financing activities	19	5	3	6	3
Net increase (decrease) in cash and cash equivalents	12	−567,408	−451,737	1	437,546
Cash paid for interest	0	13,072	10,705	—	—
Cash paid for income taxes	1,691	0	0	—	—
Capitalization of Series B preferred stock dividends	5,425	0	—	—	—
Capitalization of Series C preferred stock dividends	1,258	0	—	—	—
Conversion of Series C preferred stock to common stock	548,534	0	—	—	—
Cashless exercise of B warrants to common stock	10	0	—	—	—
Dividends accrued on preferred shares	0	59,675	0	415,523	1
Exchange of indebtedness for common shares	0	2	0	—	—
Exchange of indebtedness for preferred shares	0	930,052	0	—	—
Conversion of preferred stock to common stock	0	129,999	0	26	0
Issuance of common shares related to restricted stock units	0	216,597	0	—	—
Issuance of commitment shares related to bridge funding	0	33,297	175,619	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro